crispr- lecture 6 Flashcards
every human is born with around how many de novo mutations
70-80
“simple” genetic traits
those that are determined by a single gene
polygenic
have their roots in variation at many loci
gene therapy
We attempt to address the problem at the level of its root cause: at the gene
sickle cell disease (SC)
This was first identified in Chicago in 1910 when physician James Herrick observed weirdly “sickle shaped” red blood cells (RBCs) in the blood of
Walter Clement Noel, a dentistry student from Grenada in the West Indies. red blood cells are typically circular, donut shaped. On the basis of the difference between sickled RBCs and normal ones, SC was, in the late 1940’s, the first disease
to be attributed to a simple molecular difference, in this case between ‘normal’ hemoglobin, the oxygen-transporting molecule in RBCs, and sickling hemoglobin. Within ten years, scientists had identified the key difference, a single amino acid.
People with SC, have a single basepair mutation in their beta chains resulting in the substitution of a valine for a glutamic acid. It turns out that, under certain conditions, including a lack of oxygen, the presence of valine causes the globin molecules to stick together, to polymerize into long, relative rigid molecular cables. It’s these that cause the shape of the RBCs to distort. Sickle-shaped cells do not travel readily through capillaries, causing blockages and associated damage. People who are homozygotes for the SC allele experience many painfully debilitating symptoms and, despite improvements in therapies for containing or ameliorating the symptoms, a reduced life expectancy. It can be cured with a bone marrow transplant – red blood cells are produced by hematopoietic cells in the bone marrow – but this requires a close genetic match between recipient and donor, and is itself a risky procedure
tetramer
hemoglobin is a tetramer, made up of four
protein molecules (plus the ‘heme’ group – the iron that is key to its functioning). The tetramer consists of two “alpha” globin and two “beta”
globin chains. These are derived from two very similar genes (indeed, the two genes are evolutionarily related, being derived from an ancient gene duplication of an ancestral globin gene)
heterozygote advantage
Having an SC allele provides significant
protection against malaria
In a malarial region, the SA genotype is an at advantage over the SS and AA ones. Hence the surprisingly high frequency of S alleles,
especially in populations that either are currently, or historically have been, exposed to malaria. For people in the US derived ancestrally from African populations, the S allele may be an ever-present burden
in vivo approach
most effective in situations in we can access the target cells in a highly constrained space
examples of gene therapy
Targeting (in vivo/in vitro)
Germline genome modification (inject in embryo)
genome editing (change flawed sequence)
how can targeting be bad
how can embryonic genome editing not work for sickle cell
if someone is diagnosed at some age, you cant edit an “embryo”
explain the assembly of the crrna/cas complex
the crispr locus is transcribed into a long crispr rna precursor
this precursor is then processed by cas enzymes and rnase 111 to produce short strands of crrnaa one for each spacer sequence
the cut will only occur if the targer dna contains a
protospacer adjacent motif (pam),a 3 nucleotide long sequence a few bases downstream of the target dna
once pam is found what happens
if a target dna sequence is present complementary to the crrna the crrna will anneal to the dna bringing the tracrrna and cas9 complex along with it
the cas9 then employs its nuclease activity to make a specific cut in the target dna
two parts of cas9 complex
dna cutting protein cas9 enzyme and single guide rna